Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2016) 5 P381 | DOI: 10.1530/boneabs.5.P381

Osteoporosis: treatment

Treatment outcomes during teriparatide use in Greece: country sub-analysis of the Exfos Observational Study

Kyriakos Aloumanis1, Matthaios Savvidis2, Alexandros-Paris Repousis3, Helen Lianou1, Vangelis Drossinos1 & George Kapetanos4

10 views


1Department of Medical Research, Pharmaserve Lilly SACI, Athens, Greece; 2Private Office, Veria, Greece; 3Private Office, Trikala, Greece; 43rd Orthopedics University Clinic, Papageorgiou General Hospital, Thessaloniki, Greece.


Scope: Extended Forsteo Observational Study (ExFOS), a multinational, non-interventional, prospective, observational study aims to evaluate fracture outcomes, back pain (BP), compliance and health-related Quality of Life (QoL) in osteoporotic patients prescribed teriparatide (TPTD). We present treatment outcomes for patients (male or female) treated for up to 24 months in Greece.

Methods: Of the 440 patients enrolled in the study 416 (mean age 69.9±9.7 years) have performed at least one active treatment post-baseline visit. These were predominantly women (92.1%), at postmenopausal stage (99.7%). Self-reported parameters of health perception have been recorded throughout the study through validated questionnaires (EQ-5D). We report the observed percent and mean responses.

Results: Seventeen (4.1%) patients had an incident clinical fracture during follow-up. Adherence: 80% of subjects used the treatment through month 23; 45% continued use through month 24. BMD numerically increased in all sites. Indicatively, Lumbar BMD T-score (mean (S.D.)) increased from −3.39 (0.73) at baseline to −2.36 (0.63) at study end. BP history the last year before enrollment was reported by 88.9%. During treatment, all self-reported variables improved. Examples of BP frequency (% of patients with BP fairly often or almost daily) and BP severity (% with moderate-severe BP), EQ-5D Visual Analogue Scale (VAS) score and EQ-5D mobility (% reporting some or extreme problems) are depicted below.

Baseline3 m6 m12 m18 m24 m
BP frequency (%)68.233.522.614.11711.6
BP severity (%)76.250.432.820.922.218.6
EQ-5D VAS57.466.271.375.476.783
EQ-5D Mobility (%)57.939.029.922.517.716.2

Conclusions: Use of TPTD remains high almost throughout the follow-up. A decrease at month 24 may be due to prescribing (24 months/26 cartridges) particularities. Patients experience improvement in BP and QoL. Fracture rate was low. Results should be interpreted in the context of an observational study.

Volume 5

43rd Annual European Calcified Tissue Society Congress

Rome, Italy
14 May 2016 - 17 May 2016

European Calcified Tissue Society 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.